Proteus mirabilis resistant to carbapenems isolated from a patient with a venous leg ulcer: a case report

J Wound Care. 2022 May 2;31(5):460-464. doi: 10.12968/jowc.2022.31.5.460.

Abstract

Objective: The aim of the study was to phenotypically investigate the expression of the enzyme Klebsiella pneumoniae carbapenemase (KPC) in a Proteus mirabilis sample resistant to carbapenems, isolated from the wound of a patient with a venous leg ulcer (VLU) treated at an outpatient referral service.

Method: This was a case study conducted with a patient who had a VLU on the lower left limb. Samples were taken for the examination of microbiological material from the patient's wound, using an aseptic technique. The colonies extracted were submitted to Gram staining and biochemical tests to identify the strain. In addition, an antimicrobial susceptibility test, E-test and a modified Hodge test were performed.

Results: The identified microorganism was Proteus mirabilis, which showed resistance to cefuroxime and the carbapenems imipenem and meropenem. As well as the minimum inhibitory concentration (MIC) of 3.0μg/ml for imipenem, demonstrating resistance, there was no KPC production by the tested isolate, which presented a negative modified Hodge test.

Conclusion: The results highlight the importance of microbiological surveillance, aimed at reducing morbidity and mortality rates associated with infection by multiresistant bacteria.

Keywords: Proteus mirabilis; antimicrobial agents; leg ulcer; nursing; ulcer; venous ulcers; wound; wound care; wound healing.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenems* / pharmacology
  • Carbapenems* / therapeutic use
  • Humans
  • Imipenem / pharmacology
  • Imipenem / therapeutic use
  • Klebsiella pneumoniae
  • Leg Ulcer*
  • Microbial Sensitivity Tests
  • Proteus mirabilis
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Imipenem
  • beta-Lactamases